EUVIMEDEUVIMED entdecken
Open Access

Honokiol enhances the sensitivity of cetuximab in KRAS G13D mutant colorectal cancer through destroying SNX3-retromer complex

Qianru Zhu, Ruonan Zhang, Xiaoqing Gu, Ziming Zhao, Quan Gao, Min Chen, Qibiao Wu, Tian Xie, Xinbing Sui

Theranostics · 2024

DOI: 10.7150/thno.97180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Qianru Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China. Hauptthemen laut MEDLINE: Cetuximab, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Lignans. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CetuximabColorectal NeoplasmsProto-Oncogene Proteins p21(ras)LignansBiphenyl CompoundsMutationCell ProliferationApoptosisHumansAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysProto-Oncogene MasDrug SynergismMice, NudeDrug Resistance, NeoplasmMice, Inbred BALB CAllyl CompoundsPhenols

Stichwörter der Autor:innen

KRASSNX3cetuximabcolorectal cancerhonokiol

Substanzen

CetuximabProto-Oncogene Proteins p21(ras)LignansKRAS protein, humanhonokiolBiphenyl CompoundsProto-Oncogene MasMAS1 protein, humanAllyl CompoundsPhenols

Autor:innen und Institutionen

  • School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
  • State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China.
  • Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.

Zitieren

APA

Zhu, Q., Zhang, R., Gu, X., Zhao, Z., Gao, Q., Chen, M., Wu, Q., Xie, T., & Sui, X. (2024). Honokiol enhances the sensitivity of cetuximab in KRAS G13D mutant colorectal cancer through destroying SNX3-retromer complex. Theranostics. https://doi.org/10.7150/thno.97180

Vancouver

Zhu Q, Zhang R, Gu X, Zhao Z, Gao Q, Chen M, et al. Honokiol enhances the sensitivity of cetuximab in KRAS G13D mutant colorectal cancer through destroying SNX3-retromer complex. Theranostics. 2024. doi:10.7150/thno.97180

BibTeX
@article{Zhu2024,
  author = {Zhu, Qianru and Zhang, Ruonan and Gu, Xiaoqing and Zhao, Ziming and Gao, Quan and Chen, Min and Wu, Qibiao and Xie, Tian and Sui, Xinbing},
  title = {Honokiol enhances the sensitivity of cetuximab in KRAS G13D mutant colorectal cancer through destroying SNX3-retromer complex},
  journal = {Theranostics},
  year = {2024},
  doi = {10.7150/thno.97180}
}
Kostenlos starten →